Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10


Regulation of TAK1/TAB1-mediated IL-1β signaling by cytoplasmic PPARβ/δ.

Stockert J, Wolf A, Kaddatz K, Schnitzer E, Finkernagel F, Meissner W, Müller-Brüsselbach S, Kracht M, Müller R.

PLoS One. 2013 Apr 30;8(4):e63011. doi: 10.1371/journal.pone.0063011. Print 2013.


Inverse PPARβ/δ agonists suppress oncogenic signaling to the ANGPTL4 gene and inhibit cancer cell invasion.

Adhikary T, Brandt DT, Kaddatz K, Stockert J, Naruhn S, Meissner W, Finkernagel F, Obert J, Lieber S, Scharfe M, Jarek M, Toth PM, Scheer F, Diederich WE, Reinartz S, Grosse R, Müller-Brüsselbach S, Müller R.

Oncogene. 2013 Oct 31;32(44):5241-52. doi: 10.1038/onc.2012.549. Epub 2012 Dec 3.


High-affinity peroxisome proliferator-activated receptor β/δ-specific ligands with pure antagonistic or inverse agonistic properties.

Naruhn S, Toth PM, Adhikary T, Kaddatz K, Pape V, Dörr S, Klebe G, Müller-Brüsselbach S, Diederich WE, Müller R.

Mol Pharmacol. 2011 Nov;80(5):828-38. doi: 10.1124/mol.111.074039. Epub 2011 Aug 23.


Genomewide analyses define different modes of transcriptional regulation by peroxisome proliferator-activated receptor-β/δ (PPARβ/δ).

Adhikary T, Kaddatz K, Finkernagel F, Schönbauer A, Meissner W, Scharfe M, Jarek M, Blöcker H, Müller-Brüsselbach S, Müller R.

PLoS One. 2011 Jan 19;6(1):e16344. doi: 10.1371/journal.pone.0016344.


Reverse crosstalk of TGFβ and PPARβ/δ signaling identified by transcriptional profiling.

Stockert J, Adhikary T, Kaddatz K, Finkernagel F, Meissner W, Müller-Brüsselbach S, Müller R.

Nucleic Acids Res. 2011 Jan;39(1):119-31. doi: 10.1093/nar/gkq773. Epub 2010 Sep 15.


Transcriptional profiling identifies functional interactions of TGF β and PPAR β/δ signaling: synergistic induction of ANGPTL4 transcription.

Kaddatz K, Adhikary T, Finkernagel F, Meissner W, Müller-Brüsselbach S, Müller R.

J Biol Chem. 2010 Sep 17;285(38):29469-79. doi: 10.1074/jbc.M110.142018. Epub 2010 Jul 1.


15-hydroxyeicosatetraenoic acid is a preferential peroxisome proliferator-activated receptor beta/delta agonist.

Naruhn S, Meissner W, Adhikary T, Kaddatz K, Klein T, Watzer B, Müller-Brüsselbach S, Müller R.

Mol Pharmacol. 2010 Feb;77(2):171-84. doi: 10.1124/mol.109.060541. Epub 2009 Nov 10.


Deregulation of tumor angiogenesis and blockade of tumor growth in PPARbeta-deficient mice.

Müller-Brüsselbach S, Kömhoff M, Rieck M, Meissner W, Kaddatz K, Adamkiewicz J, Keil B, Klose KJ, Moll R, Burdick AD, Peters JM, Müller R.

EMBO J. 2007 Aug 8;26(15):3686-98. Epub 2007 Jul 19.


Specific components of prostanoid-signaling pathways are present in non-small cell lung cancer cells.

Kreutzer M, Fauti T, Kaddatz K, Seifart C, Neubauer A, Schweer H, Kömhoff M, Müller-Brüsselbach S, Müller R.

Oncol Rep. 2007 Aug;18(2):497-501.


Proteomic profile of mouse fibroblasts with a targeted disruption of the peroxisome proliferator activated receptor-beta/delta gene.

Adamkiewicz J, Kaddatz K, Rieck M, Wilke B, Müller-Brüsselbach S, Müller R.

Proteomics. 2007 Apr;7(8):1208-16.


Supplemental Content

Loading ...
Support Center